- Active not recruitingPHASE2
(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
This study is testing a new drug called avapritinib for people with a type of mastocytosis called indolent systemic mastocytosis (ISM). It compares avapritinib with a dummy pill (placebo) to see if it helps control symptoms better and is safe.
For: Indolent Systemic MastocytosisUnited States · Belgium · Canada - RecruitingPHASE4
Avapritinib Rollover Study
This study looks at the long-term safety of a medicine called avapritinib for people with mastocytosis. It's for patients who are already taking avapritinib in another study and are getting real benefits from it.
For: Mastocytosis, SystemicBelgium · Canada · Italy